Silo Pharma (SILO) Income from Continuing Operations (2018 - 2026)
Silo Pharma (SILO) posted Income from Continuing Operations of 1647117.0 for Q1 2026, down 86.85% sequentially from 881530.0 in Q4 2025, and down 59.69% YoY from 4086274.96 in Q1 2025.
Silo Pharma (SILO) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Silo Pharma has reported Income from Continuing Operations for 9 years, with the latest figure at 1647117.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 59.69% year-over-year to 1647117.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4843378.0 (down 4.77% YoY) and the FY2025 annual result came in at 3118005.0, up 20.15% from the prior year.
- Income from Continuing Operations fell to 1647117.0 in Q1 2026 per SILO's latest filing, from 881530.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 658402.0 in Q2 2022 and troughed at 1812792.0 in Q1 2023.
- A 5-year average of 1136204.18 and a median of 1031437.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 115.19% in 2022, then surged 55.78% in 2024.
- Over 5 years, Income from Continuing Operations stood at 1662831.0 in 2022, then surged by 36.76% to 1051576.0 in 2023, then plunged by 64.57% to 1730620.0 in 2024, then jumped by 49.06% to 881530.0 in 2025, then tumbled by 86.85% to 1647117.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1647117.0, 881530.0, and 1110438.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | -832,829.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -832,829.00 |
| Mar 31, 2026 | -1.65 Mn |
| Dec 31, 2025 | -881,530.00 |
| Sep 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.20 Mn |
| Mar 31, 2025 | -1.03 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Sep 30, 2024 | -928,814.00 |
| Jun 30, 2024 | -931,779.00 |
| Mar 31, 2024 | -801,667.00 |
| Dec 31, 2023 | -1.05 Mn |
| Sep 30, 2023 | -660,160.00 |
| Jun 30, 2023 | -1.01 Mn |
| Mar 31, 2023 | -1.81 Mn |
| Dec 31, 2022 | -1.66 Mn |
| Sep 30, 2022 | -983,246.00 |
| Jun 30, 2022 | -658,402.00 |
| Mar 31, 2022 | -1.21 Mn |
| Dec 31, 2021 | -1.86 Mn |
| Sep 30, 2021 | 6.47 Mn |